Skip to main content


Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs

Fig. 2

ROC curves indicating the predictive value of calprotectin and clinical predictors for disease flare within 12 months of tapering in the IMPROVED (a, c) and RETRO (b, d) studies. a, b Circulating calprotectin levels (ng/mL) at the moment of DMARD tapering/stopping. c, d Comparison of models including clinical predictors only (dashed line) and clinical predictors in combination with circulating calprotectin levels (solid line). The p value is based on the test for equality of AUCs

Back to article page